Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    "Placenta Praevia" | "Antioxidants"
Previous Study | Return to List | Next Study

ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis (Accreta, Increta, Percreta).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02270593
Recruitment Status : Unknown
Verified October 2014 by sibel özler, Zekai Tahir Burak Women's Health Research and Education Hospital.
Recruitment status was:  Recruiting
First Posted : October 21, 2014
Last Update Posted : October 21, 2014
Sponsor:
Information provided by (Responsible Party):
sibel özler, Zekai Tahir Burak Women's Health Research and Education Hospital

Brief Summary:
Placenta previa totalis (accreta, increta, percreta); ADAMTS and proteoglycans and the oxidant / antioxidant enzyme levels.

Condition or disease
Placenta Previa

Detailed Description:
Placenta previa totalis (accreta, increta, percreta) of pregnant women in the maternal serum, fetal membranes (placenta) and hysterectomy of women with myometrial strips measured the ADAMTS and proteoglycans expression levels, and the oxidant / antioxidant enzyme levels.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 30 participants
Observational Model: Case Control
Time Perspective: Prospective
Target Follow-Up Duration: 2 Years
Official Title: ADAMTS, Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis(Accreta, Increta, Percreta)
Study Start Date : August 2013
Estimated Primary Completion Date : December 2014
Estimated Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antioxidants

Group/Cohort
Placenta previa
first; maternal serum, fetal membranes (placenta) and maternal myometrial samples will be investigated for ADAMTS, Proteoglycans and oxidative/antioxidative enzyme status levels in patients with placental invasion anomalies Placenta Previa totalis by ELISA, western blot, immunohystochemistry and PCR (polymerase chain reaction).



Primary Outcome Measures :
  1. ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of maternal serum in patients with the diagnosis of Placenta Previa (Accreta, increta, percreta) [ Time Frame: Up to 6 months ]

Secondary Outcome Measures :
  1. ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of myometrial samples in patients with the diagnosis of Placenta Previa (Accreta, increta, percreta) [ Time Frame: Up to 6 months ]
  2. ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Fetal Membranes in patients with the diagnosis of Placenta Previa (Accreta, increta, percreta) [ Time Frame: Up to 6 months ]
  3. placenta previa totalis in the development, progression and in exacerbating; ADAMTS and proteoglycans, to determine the relationship of changes in expression. [ Time Frame: Up to 2 years ]

Biospecimen Retention:   None Retained
serum and fetal membranes (placenta) and maternal myometrial sample


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
tertiary health institutions
Criteria

Inclusion Criteria:

  • pregnant women diagnosed with placenta previa by obstetric ultrasound and doppler

Exclusion Criteria:

  • Pregnant women with comorbid diseases other than previa totalis .

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02270593


Contacts
Layout table for location contacts
Contact: sibel özler, md 05457970257 sibelozler@gmail.com

Locations
Layout table for location information
Turkey
Zekai Tahir Burak Women's Health Education and Research Hospital Recruiting
Ankara, Turkey
Contact: SİBEL ÖZLER, MD    0(312)30650000      
Principal Investigator: AHMET NURİ DANIŞMAN, MD         
Sub-Investigator: ALİ TURHAN ÇAĞLAR, MD         
Principal Investigator: SİBEL ÖZLER, MD         
Sponsors and Collaborators
Zekai Tahir Burak Women's Health Research and Education Hospital
Investigators
Layout table for investigator information
Study Director: ahmet nuri danısman, md zekai tahir burak women's health education and research hospital

Additional Information:

Layout table for additonal information
Responsible Party: sibel özler, ADAMTS, Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis(Accreta, Increta, Percreta), Zekai Tahir Burak Women's Health Research and Education Hospital
ClinicalTrials.gov Identifier: NCT02270593     History of Changes
Other Study ID Numbers: prospective study-2
First Posted: October 21, 2014    Key Record Dates
Last Update Posted: October 21, 2014
Last Verified: October 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Placenta Previa
Obstetric Labor Complications
Pregnancy Complications
Placenta Diseases
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs